Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Study Purpose
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month treatment period.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 4 Years - 7 Years |
Gender | All |
Key
Inclusion Criteria:
- - Aged 4 through 7 years at Visit 1 (screening).
- - Physician-diagnosed peanut allergy or children with a well-documented medical history of IgE-mediated reactions after ingestion of peanut and currently following a strict peanut-free diet.
- - Peanut-specific IgE of >0.7 kilo allergy unit per liter (kUA/L) and a positive peanut SPT with the largest wheal diameter of ≥6 millimeter (mm) at Visit 1.
- - An ED of ≤100 mg peanut protein at screening DBPCFC.
Exclusion Criteria:
- - Severe generalized dermatologic disease involving the application area (interscapular region) - Uncontrolled persistent asthma.
- - Past or current immunotherapy for peanut allergy, including oral immunotherapy (OIT).
- - Current immunotherapy for any allergen (including food allergy, allergic rhinitis and/or insect allergy), or treatment with any monoclonal antibody or biologic immunomodulatory therapy within 6 months prior to Visit 1.
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05741476 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
DBV Technologies |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
N/A |
Principal Investigator Affiliation | N/A |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Recruiting |
Countries | Australia, Canada, France, Germany, Ireland, Netherlands, Spain, United Kingdom, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Allergy, Peanut |
The overall maximum study duration for each participant will be approximately 58 weeks: Screening Period of 4-weeks, Treatment Period of 12-months and Follow-up Period of 2-weeks. During the 4-week Screening Period, participants are required to meet 2 sequential screening parameters to determine eligibility prior to randomization:
- - Assessment of peanut skin prick test (SPT) and serum peanut immunoglobulin-E (IgE) - Peanut double-blind placebo-controlled food challenge (DBPCFC) to confirm peanut allergy and establish an entry peanut eliciting dose (ED).
Arms
Experimental: DBV712 250 mcg
Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
Placebo Comparator: Placebo
Participants will apply DBV712 matching placebo epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
Interventions
Drug: - DBV712
DBV712 250 mcg epicutaneous system.
Other: - Placebo
DBV712 matching placebo epicutaneous system.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Recruiting
Address
DBV Investigative Site
Birmingham, Alabama, 35233
Status
Recruiting
Address
DBV Investigative Site
Tucson, Arizona, 85724
Status
Recruiting
Address
DBV Investigative Site
Little Rock, Arkansas, 72205
Status
Recruiting
Address
DBV Investigative Site
Los Angeles, California, 90027
Status
Recruiting
Address
DBV Investigative Site
Los Angeles, California, 90095
Status
Recruiting
Address
DBV Investigative site
Mission Viejo, California, 92691
Status
Recruiting
Address
DBV Investigative Site
San Diego, California, 92123
Status
Recruiting
Address
DBV Investigative Site
San Francisco, California, 94158
Status
Recruiting
Address
DBV Investigative Site
San Jose, California, 92691
Status
Recruiting
Address
DBV Investigative Site
Aurora, Colorado, 80045
Status
Recruiting
Address
DBV Investigative Site
Colorado Springs, Colorado, 80907
Status
Recruiting
Address
DBV Investigative Site
Washington, District of Columbia, 20010
Status
Recruiting
Address
DBV Investigative Site
Hollywood, Florida, 33021
Status
Recruiting
Address
DBV Investigative Site
Miami, Florida, 33136
Status
Recruiting
Address
DBV Investigative Site
Tampa, Florida, 33613
Status
Recruiting
Address
DBV Investigative Site
Tampa, Florida, 33620
Status
Recruiting
Address
DBV Investigative site
Atlanta, Georgia, 30329
Status
Recruiting
Address
DBV Investigative Site
Marietta, Georgia, 30002
Status
Recruiting
Address
DBV Investigative Site
Chicago, Illinois, 60611
Status
Recruiting
Address
DBV Investigative Site
Normal, Illinois, 61761
Status
Recruiting
Address
DBV Investigative Site
Indianapolis, Indiana, 46202
Status
Recruiting
Address
DBV Investigative Site
Louisville, Kentucky, 40215
Status
Recruiting
Address
DBV Investigative Site
Baltimore, Maryland, 21287
Status
Recruiting
Address
DBV Investigative Site
Chevy Chase, Maryland, 20815
Status
Recruiting
Address
DBV Investigative Site
Boston, Massachusetts, 02114
Status
Recruiting
Address
DBV Investigative Site
Boston, Massachusetts, 02115
Status
Recruiting
Address
DBV Investigative Site
Taunton, Massachusetts, 02780
Status
Recruiting
Address
DBV Investigative Site
Ann Arbor, Michigan, 48106
Status
Recruiting
Address
DBV Investigative Site
Ypsilanti, Michigan, 48106
Status
Recruiting
Address
DBV Investigative Site
Maplewood, Minnesota, 55109
Status
Recruiting
Address
DBV Investigative Site
Kansas City, Missouri, 64108
Status
Recruiting
Address
DBV Investigative Site
Great Neck, New York, 11021
Status
Recruiting
Address
DBV Investigative Site
New York, New York, 10016
Status
Recruiting
Address
DBV Investigative Site
New York, New York, 10029
Status
Recruiting
Address
DBV Investigative Site
Rochester, New York, 14642
Status
Recruiting
Address
DBV Investigative Site
Chapel Hill, North Carolina, 27599
Status
Recruiting
Address
DBV Investigative Site
Cincinnati, Ohio, 45229
Status
Recruiting
Address
DBV Investigative Site
Cleveland, Ohio, 44106
Status
Recruiting
Address
DBV Investigative Site
Cleveland, Ohio, 44195
Status
Recruiting
Address
DBV Investigative Site
Columbus, Ohio, 43205
Status
Recruiting
Address
DBV Investigative Site
Philadelphia, Pennsylvania, 19111
Status
Recruiting
Address
DBV Investigative Site
Pittsburgh, Pennsylvania, 15224
Status
Recruiting
Address
DBV Investigative Site
Memphis, Tennessee, 38105
Status
Recruiting
Address
DBV Investigative Site
Nashville, Tennessee, 37232
Status
Recruiting
Address
DBV Investigative Site
Austin, Texas, 78723
Status
Recruiting
Address
DBV Investigative Site
Dallas, Texas, 75235
Status
Recruiting
Address
DBV Investigative Site
Houston, Texas, 77030
Status
Recruiting
Address
DBV Investigative Site
Seattle, Washington, 98115
Status
Not yet recruiting
Address
DBV Investigative Site
Madison, Wisconsin, 53792
International Sites
Status
Recruiting
Address
DBV Investigative Site
Adelaide, , 5006
Status
Recruiting
Address
DBV Investigative Site
Nedlands, , 6009
Status
Recruiting
Address
DBV Investigative Site
Parkville, , 3052
Status
Recruiting
Address
DBV Investigative Site
Richmond, , 3121
Status
Recruiting
Address
DBV Investigative Site
South Brisbane, , 4101
Status
Recruiting
Address
DBV Investigative Site
Westmead, , 2145
Status
Recruiting
Address
DBV Investigative Site
Vancouver, British Columbia, V6H 3V4
Status
Recruiting
Address
DBV Investigative Site
Winnipeg, Manitoba, R3J 059
Status
Recruiting
Address
DBV Investigative Site
Burlington, Ontario, L7L6W6
Status
Recruiting
Address
DBV Investigative Site
North York, Ontario, M3B3S6
Status
Recruiting
Address
DBV Investigative Site
Ottawa, Ontario, M5G 1X8
Status
Recruiting
Address
DBV Investigative Site
Toronto, Ontario, M3B3S6
Status
Recruiting
Address
DBV Investigative Site
Montréal, Quebec, H3T 1C4
Status
Recruiting
Address
DBV Investigative Site
Montréal, Quebec, H3T 1C5
Status
Recruiting
Address
DBV Investigative Site
Québec, Quebec, G1v4W2
Status
Recruiting
Address
DBV Investigative Site
Hamilton, , L8SIG5
Status
Not yet recruiting
Address
DBV Investigative Site
Angers, Cedex, 09
Status
Not yet recruiting
Address
DBV Investigative Site
Brest, , 29200
Status
Not yet recruiting
Address
DBV Investigative Site
Bron, , 69500
Status
Not yet recruiting
Address
DBV Investigative Site
Nice, , 06200
Status
Not yet recruiting
Address
DBV Investigative Site
Strasbourg, , 67091
Status
Not yet recruiting
Address
DBV Investigative Site
Vandœuvre-lès-Nancy, , 54511
Status
Not yet recruiting
Address
DBV Investigative Site
Düsseldorf, , 40217
Status
Not yet recruiting
Address
DBV Investigative Site
Frankfurt, , 60590
Status
Not yet recruiting
Address
DBV Investigative Site
Ulm, , 89075
Status
Not yet recruiting
Address
DBV Investigative Site
Cork, , T12 DC4A
Status
Not yet recruiting
Address
DBV Investigative Site
Dublin, , D08HP97
Status
Recruiting
Address
DBV Investigative Site
Rotterdam, , 3015 CN
Status
Not yet recruiting
Address
DBV Investigative Site
Utrecht, , 3584 EA
Status
Recruiting
Address
DBV Investigative Site
Madrid, , 28009
Status
Not yet recruiting
Address
DBV Investigative Site
Madrid, , 28010
Status
Not yet recruiting
Address
DBV Investigative Site
Madrid, , 28034
Status
Not yet recruiting
Address
DBV Investigative Site
Málaga, , CP 29011
Status
Not yet recruiting
Address
DBV Investigative Site
London, , SE1 7ETH
Status
Recruiting
Address
DBV Investigative Site
London, , W2 1NY
Status
Not yet recruiting
Address
DBV Investigative Site
Manchester, , M13 9WL
Status
Not yet recruiting
Address
DBV Investigative Site
Sheffield, , S10 2TH
Status
Not yet recruiting
Address
DBV Investigative Site
Southampton, , SO16 6YD